The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended that China lose its Most-Favored Nation (MFN) tariff status. Referencing the decision to grant China permanent MFN status in 2001, Speaker McCarthy said in remarks on the House floor yesterday…
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
China’s Zero Covid protests should persuade Washington, businesses, and consumers that dependence on China for manufacturing American goods will dull the shine off iconic American brands. Political risks are rising.
Inflation remains due to supply chain problems. From China’s Zero Covid to European energy costs, the price of outsourcing manufacturing is getting high. Why reshoring is an inflation curb.
The multilateral trading system, birthed on October 30, 1947, was unceremoniously knifed and left for dead by President Biden’s signing of the Inflation Reduction Act. This is an unprecedented move by the United States in our seventy-five year history as part of that system. Retaliation will come from much of the world. Here is what…
CPA economists Jeff Ferry and Amanda Mayoral explain the continued deterioration of market share for domestic producers versus imports.
